Cardima, Inc. (OTCBB: CADM) -- LeadingElectrophysiology Physicians at Guy's and St. Thomas Hospital, London, UK,have concluded a portion of a study for the treatment of AtrialFibrillation ("AF"). Guy's and St. Thomas Hospital is a leading cardiaccenter located in the center of London, England. Patients with bothparoxysmal and persistent AF were included in this trial. Cardima's EPAblation System is being used to treat the patients. To date, Guy's andSt. Thomas Hospital has treated over 110 AF patients using the CardimaSystem.
This UK single center study is on-going, and to date, 30 patients havecompleted the follow-up monitoring necessary to define success. Theprincipal investigator of the study, Jaswinder Gill MD, FRCP, recentlycompiled this data on the first 30 patients and presented it at the FourthAnnual Congress of the European Cardiac Arrhythmia Society (ECAS) inMarseille, France on April 13-15th, 2008. His abstract, titled:"Performance of a Novel Linear Catheter Ablating System for Left and RightAtrial Compartmentalization to Reproduce MAZE Operation" has also beenaccepted for publication by the Journal of Interventional Cardiology andElectrophysiology ("JICE") and is included in Volume 22:1, 2008.
In commenting on his study, Dr. Gill stated: "This early patient datademonstrates that the Cardima EP Ablation System is safe for use in theleft atrium. It also illustrates how the Cardima catheter, theREVELATION® T-Flex, can be used to create lesions in the left and rightatrium that mimic the Cox Maze for the treatment of AF in a safe andeffective manner. Our team looks forward to working with Cardima to expandour study and build a robust body of data that will assist in establishingthis linear ablation system as a safe and effective tool for the treatmentof AF. Identifying new patient treatment options for AF that are safe andeffective is an important public health issue for the UK and many countriesaround the world."
Cardima's CEO, Robert Cheney, acknowledged the important contribution byDr. Gill and the team at Guy's and St. Thomas Hospital, "Cardima is veryproud to be associated with Guy's and St. Thomas Hospital, a leader incardiac care, and the highly professional team led by Dr. Gill. The datapresented will benefit patients across the UK and the European Union whoare in need of AF treatment. We look forward to working with Dr. Gill andhis team to expand this study to more centers in the UK over the comingmonths."
About Cardima
Cardima, Inc. has developed the PATHFINDER®, TRACER® and VUEPORT®Series of diagnostic catheters, the NAVIPORT® Series of guidingcatheters, the REVELATION® Series of ablation catheters, the SurgicalAblation System with its series of ablation probes, and the INTELLITEMP®Energy Management Device Series for RF (radiofrequency) energy management.These devices are CE marked and/or received U.S.
